glp-1 medications dizziness side effect Exploring the Effects of Receptor Agonist: To Ensure Its Optimal Positioning The Risk of Vestibular Disorders

Instead, it reflects the chronic nature of obesity and metabolic disease

Voretigene neparvovec-rzyl (Luxturna) was approved by FDA in December of 2017 and is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy

In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes

In the 1970s, Russian scientist Professor Vladimir Khavinson was obsessed with reversing aging

doi: 10.2147/NDT.S199746 66

Separately, Indian clinical reviews of GLP-1 analogues such as exenatide and liraglutide found effects on HbA1c, fasting glucose, and post-meal glucose broadly comparable to global data, along with a genuinely low rate of hypoglycemia [4]